AK
Aktis Oncology, Inc.
AKTS · NASDAQ
$24.06 -5.91% (-$1.51)
1M -2.87%
Market Cap $1.28B
P/E Ratio -
Div. Yield -
ROE 35.78%
Piotroski F-Score Weak
2/9Valuation
0 /100
Expensive P/S 197.77x
P/E N/A
EV/EBITDA N/A
Growth
-
N/A EPS growth N/A
Rev. growth N/A
FCF growth N/A
Profitability
20 /100
Weak Gross margin 100.00%
Net margin 980.93%
Op. margin 1,149.52%
Quality
0 /100
Poor ROIC 31.79%
ROE 35.78%
ROA 24.06%
Debt
100 /100
Low Current ratio 7.37x
Debt/Equity N/A
Int. coverage N/A
Stability
47 /100
Moderate Beta 0.45x
EPS volatility 36.42%
Profitable years 0
Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe
Întreabă StockBot despre AKTS
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Matthew Roden
Employees
79
Headquarters
Boston
Evenimente viitoare
12 NOV.
Earnings
Upcoming earnings report